Cargando…
ASO Author Reflections: First Do No Harm—Revisiting Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Trials to Reduce the Risk of Peritoneal Metastasis
Autores principales: | Yurttas, Can, Königsrainer, Alfred, Löffler, Markus W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590993/ https://www.ncbi.nlm.nih.gov/pubmed/34117575 http://dx.doi.org/10.1245/s10434-021-10263-z |
Ejemplares similares
-
ASO Author Reflections: Can Patient Selection for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy be Improved?
por: Graf, Wilhelm, et al.
Publicado: (2019) -
ASO Author Reflections: Routine Omentectomy During Cytoreductive Surgery and HIPEC
por: Khan, Sohini, et al.
Publicado: (2022) -
ASO Author Reflections: The Timing of Onset of Peritoneal Metastases from Colorectal Carcinoma Is Not an Independent Predictor of Survival Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy
por: Dietz, Michelle V., et al.
Publicado: (2022) -
ASO Author Reflections: Changes in Coagulation Biomarkers and the Risk for Venous Thromboembolism After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
por: Dranichnikov, Paul
Publicado: (2021) -
ASO Author Reflections: Preventing Nephrotoxicities in Ovarian Cancer Patients Undergoing HIPEC
por: Senguttuvan, Rosemary N., et al.
Publicado: (2023)